Introduction
For pharmaceutical manufacturers, choosing a reliable excipient supplier is about more than product quality. Consistent product performance, sufficient production capacity, and long-term supply stability are equally important.
At Westpoint Pharma, we understand these requirements and have established a large-scale manufacturing system for pharmaceutical mannitol. With an annual production capacity of approximately 26,000 metric tons, we provide reliable supply support for pharmaceutical manufacturers in both domestic and international markets.
Our DESU® Mannitol portfolio combines proprietary secondary granulation technologies, advanced manufacturing processes, and a quality management system aligned with international GMP standards.
From production capacity to powder properties and formulation performance, Westpoint Pharma is committed to providing pharmaceutical manufacturers with consistent, high-performance excipient solutions.
1. What Is Westpoint Pharma's Mannitol Production Capacity?
Westpoint Pharma operates manufacturing facilities in the China Medical City, Taizhou, Jiangsu Province, China, with production facilities located in Buildings G56 and G123.
Our pharmaceutical mannitol production capacity reaches approximately 26,000 metric tons per year, providing the manufacturing scale required to support large-volume orders and long-term customer demand.
With large-scale and continuous production capabilities, we are positioned to support pharmaceutical manufacturers requiring stable, long-term supplies of pharmaceutical-grade mannitol.
For international customers, this production capacity provides a strong foundation for supply continuity and procurement planning.
2. How Does Westpoint Pharma Ensure Consistent Quality and Supply?
Production capacity alone does not guarantee reliable supply. Consistent manufacturing processes and effective quality management are equally important.
At Westpoint Pharma, our supply assurance is supported by three key foundations:
Modern Manufacturing Facilities
Our manufacturing base in China Medical City provides the production infrastructure needed for large-scale pharmaceutical excipient manufacturing.
Quality Management System
Our quality management system is aligned with international GMP standards, supporting consistent manufacturing and product quality control.
Proprietary Secondary Granulation Technology
We have developed proprietary patented secondary granulation processes for pharmaceutical mannitol. Through controlled particle engineering and manufacturing processes, we focus on maintaining consistent powder characteristics and product performance between batches.
These capabilities enable Westpoint Pharma to support long-term, large-volume customer supply requirements while maintaining product quality consistency.
3. What Makes DESU® Mannitol Different?
The DESU® Mannitol portfolio offers differentiated powder properties, pharmaceutical suitability, and manufacturing performance through proprietary particle engineering technologies.
Our main product categories include spray-dried mannitol and crystalline mannitol.
3.1 Excellent Powder Properties
DESU® Mannitol SD Series – Spray-Dried Mannitol
DESU® Mannitol SD Series, including DESU® Mannitol 200SD, features a porous agglomerated particle structure designed to support favorable powder properties.
Key characteristics include:
Good Powder Flowability
Angle of repose of approximately 39°.
Favorable Flow Characteristics
Hausner ratio of approximately 1.21.
Excellent Compressibility
Suitable for direct compression applications.
These powder characteristics support consistent powder feeding, die filling, and tablet manufacturing.
DESU® Mannitol C Series – Crystalline Mannitol
DESU® Mannitol C Series, including 160C and 50C, is produced using secondary granulation technology that promotes microcrystalline attachment to particle surfaces.
This engineered particle structure supports applications involving granulation and compression in combination with other excipients.
3.2 Pharmaceutical Suitability
DESU® Mannitol offers several characteristics that make it suitable for pharmaceutical formulation development:
Low Hygroscopicity
Good Chemical Stability
Rapid Dissolution
Distinctive Cooling Sensation
Does Not Participate in Sugar Metabolism
These characteristics make DESU® Mannitol suitable for evaluating in chewable tablets, orally disintegrating tablets (ODTs), dispersible tablets, and other formulations requiring favorable sensory properties and stability.
3.3 Robust Manufacturing Performance
DESU® Mannitol exhibits predominantly brittle deformation behavior, providing favorable compression characteristics.
Its compression performance is relatively insensitive to lubricant mixing time, including mixing with magnesium stearate.
This high process tolerance helps reduce the impact of lubricant mixing variations and supports direct compression process scale-up and more stable manufacturing operations.
3.4 Comparable Performance to European Products
The key powder properties, tablet performance, and microstructure of DESU® Mannitol demonstrate a high degree of consistency with comparable European products.
Relevant evaluation characteristics include:
Powder Properties
Tablet Hardness
Tablet Friability
Particle Microstructure
This level of performance comparability provides the technical feasibility for DESU® Mannitol to serve as an alternative to comparable imported products, supporting pharmaceutical manufacturers seeking reliable excipient sourcing options.
4. Can Mannitol Be Combined with Microcrystalline Cellulose (MCC)?
Yes. Combining DESU® Mannitol with microcrystalline cellulose (MCC) provides complementary formulation advantages.
Mannitol contributes favorable sensory properties, including a pleasant cooling sensation, while MCC provides important compression and binding functionality.
Their combination can help pharmaceutical manufacturers balance two important formulation requirements:
Sensory Optimization
Mannitol helps improve mouthfeel and provides a refreshing cooling sensation, making it valuable in taste-sensitive oral formulations.
Manufacturing Stability
The combination of mannitol and MCC can help balance powder processing and tablet manufacturing performance.
For direct compression formulations, this combination offers an approach to addressing the challenge of achieving both acceptable sensory properties and stable production performance.
At Westpoint Pharma, we focus on developing pharmaceutical excipients with complementary functional properties to support different formulation requirements.
5. Why Choose Westpoint Pharma as Your Mannitol Supplier?
Selecting a pharmaceutical excipient manufacturer requires consideration of production scale, quality consistency, product performance, and long-term supply capabilities.
Westpoint Pharma combines these capabilities through:
Large-Scale Manufacturing Capacity
Approximately 26,000 metric tons of annual mannitol production capacity supports large-volume procurement requirements.
Stable Quality Management
A quality management system aligned with international GMP standards supports consistent product manufacturing.
Proprietary Manufacturing Technologies
Patented secondary granulation and particle engineering processes help optimize powder characteristics and manufacturing performance.
Comprehensive Product Portfolio
DESU® Mannitol includes SD Series spray-dried grades and C Series crystalline grades for different pharmaceutical applications.
Technical Application Support
Through the Westpoint Excipients platform, we aim to provide pharmaceutical manufacturers worldwide with reliable products and technical support for excipient selection and formulation development.
Conclusion
A reliable pharmaceutical mannitol supplier needs more than sufficient production capacity. Consistent quality, robust manufacturing processes, and competitive product performance are essential to supporting long-term pharmaceutical production.
With an annual production capacity of approximately 26,000 metric tons, proprietary secondary granulation technologies, and a comprehensive DESU® Mannitol portfolio, Westpoint Pharma is committed to providing pharmaceutical manufacturers with reliable and high-performance mannitol solutions.
From DESU® Mannitol 200SD spray-dried mannitol to our crystalline C Series, we focus on delivering consistent powder properties and dependable manufacturing performance.
Through Westpoint Pharma and Westpoint Excipients, we continue to strengthen our position as a pharmaceutical excipients manufacturer and a reliable partner for global pharmaceutical manufacturers.
Westpoint Pharma
Excipient Technology for Better Formulation Performance.
Explore our pharmaceutical excipient portfolio at www.westpointexcipients.com.